CompletedPhase 2NCT00255346

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Studying Hypereosinophilic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Hagop M Kantarjian, MD
M.D. Anderson Cancer Center
Intervention
Dasatinib (BMS-354825)(drug)
Enrollment
68 enrolled
Eligibility
18 years · All sexes
Timeline
20052017

Study locations (1)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00255346 on ClinicalTrials.gov

Other trials for Hypereosinophilic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypereosinophilic syndrome

← Back to all trials